PPARg knockdown or treatment with PPARg antagonists has been shown to suppress hypermalignant subpopulations of breast cancer [30, 31], liver cancer [32, 33], prostate cancer [34] and brain cancer [35–37]. This evidence concerns the gene PPARG and prostate carcinoma.